AZN Stock Analysis: Buy, Sell, or Hold?
AZN - AstraZeneca PLC
$184.23
2.65 (1.46%)
▲
5d:
+1.3%
30d:
-10.04%
90d:
-12.05%
HOLD
MODERATE Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: Apr 29, 2026
0d
Get Alerted When AZN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: AZN is fairly valued with market pricing in 2.9% annual growth. Fine to hold or accumulate slowly on dips.
📊 HOLD: AZN is fairly valued with market pricing in 2.9% annual growth. Fine to hold or accumulate slowly on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$229.54
Based on 9.3% avg growth
INTRINSIC VALUE TODAY
$142.53
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: AZN is currently trading at $184.23, which is considered oversold relative to its 30-day fair value range of $183.68 to $201.02. The stock's valuation (Forward PE: 30.8) is in line with its historical norms (28.3). At these levels, the market is pricing in 2.9% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, AZN is in a strong uptrend. The price is currently testing key support at $180.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: AZN has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $224.49 (+23.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, AZN is in a strong uptrend. The price is currently testing key support at $180.00. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: AZN has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $224.49 (+23.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$183.68 -
$201.02
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
58.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 23.6% below Wall St target ($224.49)
- NEUTRAL: Market pricing in 2.9% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$183.68 -
$201.02
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$180.00
Resistance Level
$187.78
Current Trend
Strong Uptrend
Technical data as of
May 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
30.76
Wall Street Target
$224.49
(+23.6%)
Revenue Growth (YoY)
12.5%
Earnings Growth (YoY)
5.3%
Profit Margin
17.2%
Valuation Premium vs History
+2.9% premium
PE vs Historical
30.8 vs 28.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.9%
(market-implied from PE analysis)
1-Year Target
$186.85
(+3%)
2-Year Target
$192.26
(+6%)
3-Year Target
$197.84
(+9%)
3-Yr Target (if PE normalizes)
(PE: 31→28)
PE COMPRESSION
$182.03
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 30.8, Growth: 14.6%)
$273.42
(+51%)
Base:
(SPY PE: 22.1, Growth: 14.6%)
$196.18
(+8%)
Bear:
(PE: 18.8, Growth: 14.6%)
$166.76
(-8%)
📈
Valuation based on Current Earnings
Trailing PE: 27.21 | Current EPS (TTM): $6.64
Bull Case
$176.70
(-3%)
Analyst growth -11.1%, PE expands to 29.9
Base Case
$160.64
(-12%)
Market implied -11.1%, PE stable at 27.2
Bear Case
$122.86
(-32%)
Severe decline -20.0%, PE contracts to 23.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: May 18, 2026 12:20 PM ET
Data refreshes hourly during market hours. Next update: 1:20 PM
Data refreshes hourly during market hours. Next update: 1:20 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AZN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
29 analysts |
$1210 | 62 BUY |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$158 | 61 BUY |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$253 | 65 BUY |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$218 | 63 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$352 | 60 HOLD |
